BIO INX's 3D-Printed Scaffold Regenerated Cartilage in Rabbit Knees

A Tiny Scaffold with a Real Result

Cartilage has a lousy repair record. Damage it in a knee and it tends to stay damaged, because the tissue has almost no ability to heal itself. A team at TU Wien has now shown that 3D-printed micro-scaffolds made from a biodegradable resin can change that, at least in rabbits. After twelve weeks, defects treated with the printed implants had grown tissue reaching 91% of the thickness of natural cartilage.

The study, published in the European Polymer Journal, is the first to move this particular micro-scaffold strategy out of a petri dish and into a living animal. The scaffolds themselves are tiny, about 0.3 millimeters across, roughly the size of a grain of sand. They were printed using multiphoton lithography, a laser-based technique that builds structures point by point at resolutions below one micrometer.

The Material Is the Story

The scaffolds were made from DEGRAD INX, a resin developed by Belgian company BIO INX. It had to do three things at once: print at extremely high resolution, support living cartilage cells, and disappear as new tissue formed. That combination is what makes the result notable. High-resolution bioprinting has been possible for years, but finding a material that is also biodegradable and biocompatible enough for a joint is harder.

Researchers led by Professor Aleksandra Ovsianikov, with PhD student Oliver Kopinski-Grunwald and several Vienna trauma centers, printed the spherical scaffolds and seeded them with cartilage cells grown from stem cells. The cell-loaded spheres were then assembled into a larger implant and placed into critical-sized osteochondral defects, injuries that affect both cartilage and the bone beneath it and are too large to heal on their own.

From Lab Dish to Living Joint

Until now, the micro-scaffold approach had mostly been demonstrated in vitro. This experiment showed it could work inside a real knee. Histological analysis described the regenerated tissue as nearly normal cartilage. The untreated control group performed noticeably worse, which gives the 91% figure its weight.

Professor Ovsianikov's group has been refining this strategy for about a decade. That timeline is typical for this corner of 3D printing, where validation and certification move slowly because the stakes are high.

What This Could Mean for Patients

The most practical implication is also the least invasive. Because the building blocks are small and cell-loaded, they could potentially be injected into a cartilage defect without fully opening the joint. The blocks would adapt to the shape of the injury, mature into cartilage, and leave the scaffold material to break down naturally.

That future is still years away from human trials. But the result is a clear step forward for regenerative medicine, and another example of why the most important advances in 3D printing sometimes happen at scales too small to see with the naked eye.